Are any ICPIs being investigated for the treatment of thyroid cancer?
- Small, ongoing clinical trials testing CTLA-4, PD-1, and PD-L1 inhibitors are underway in combination with other treatment modalities in patients with anaplastic, poorly differentiated, and recurrent differentiated thyroid cancers.
- In a recent case report, a patient with anaplastic thyroid cancer showing BRAF and PD-L1 positivity had complete clinical and radiographic remission 20 months after treatment with emurafenib and nivolumab.
